Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation

Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compa...

Full description

Saved in:
Bibliographic Details
Published inBone marrow transplantation (Basingstoke) Vol. 55; no. 9; pp. 1784 - 1795
Main Authors Harada, Kaito, Fuji, Shigeo, Seo, Sachiko, Kanda, Junya, Ueki, Toshimitsu, Kimura, Fumihiko, Kato, Koji, Uchida, Naoyuki, Ikegame, Kazuhiro, Onizuka, Makoto, Matsuoka, Ken-ichi, Doki, Noriko, Kawakita, Toshiro, Onishi, Yasushi, Yano, Shingo, Fukuda, Takahiro, Takanashi, Minoko, Kanda, Yoshinobu, Atsuta, Yoshiko, Ogata, Masao
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.09.2020
Nature Publishing Group
Subjects
692/699
692/700/1750
Antithymocyte globulin
Blood
Cell Biology
Comparative analysis
Cord blood
Engraftment
Fatalities
Fetal Blood
Graft rejection
Graft vs Host Disease
Graft-versus-host reaction
Grafting
Grafts
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
Humans
Internal Medicine
Medicine
Medicine & Public Health
Mortality
Public Health
Stem cell transplantation
Stem Cells
Transplantation
Transplantation Conditioning
Transplants & implants
Online AccessGet full text

Cover

Abstract Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID ( n  = 129) and CB ( n  = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P  < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P  = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
AbstractList Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID (n = 129) and CB (n = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with haploidentical donor (HID) or cord blood (CB), no study has compared the performances of these two sources. Using nationwide registration data, we compared the transplant outcomes of patients who developed GF and underwent salvage transplantation from HID ( n  = 129) and CB ( n  = 570) from 2007 to 2016. The HID group demonstrated better neutrophil recovery (79.7 vs. 52.5% at 30 days, P  < 0.001). With a median follow-up of 3 years, both groups demonstrated similar overall survival (OS) and nonrelapse mortality (NRM; 1-year OS, 33.1 vs. 34.6% and 1-year NRM, 45.1 vs. 49.8% for the HID and CB groups). After adjustments for other covariates, OS did not differ in both groups. However, HID was associated with a lower NRM (hazard ratio, 0.71; P  = 0.038) than CB. The incidence of acute graft-versus-host disease (GVHD)-related deaths was significantly higher in the HID group, although infection-related deaths were observed more frequently in the CB group. HID may be a promising salvage SCT option after GF due to its faster engraftment and low NRM.
Audience Academic
Author Ueki, Toshimitsu
Kato, Koji
Fuji, Shigeo
Kanda, Junya
Seo, Sachiko
Harada, Kaito
Takanashi, Minoko
Yano, Shingo
Ikegame, Kazuhiro
Atsuta, Yoshiko
Ogata, Masao
Onishi, Yasushi
Kimura, Fumihiko
Onizuka, Makoto
Doki, Noriko
Kanda, Yoshinobu
Uchida, Naoyuki
Matsuoka, Ken-ichi
Fukuda, Takahiro
Kawakita, Toshiro
Author_xml – sequence: 1
  givenname: Kaito
  orcidid: 0000-0002-8462-7550
  surname: Harada
  fullname: Harada, Kaito
  email: k.harada@fuji.tokai-u.jp
  organization: Department of Hematology and Oncology, Tokai University School of Medicine
– sequence: 2
  givenname: Shigeo
  surname: Fuji
  fullname: Fuji, Shigeo
  organization: Department of Hematology, Osaka International Cancer Institute
– sequence: 3
  givenname: Sachiko
  surname: Seo
  fullname: Seo, Sachiko
  organization: Department of Hematology and Oncology, Dokkyo Medical University School of Medicine
– sequence: 4
  givenname: Junya
  orcidid: 0000-0002-6704-3633
  surname: Kanda
  fullname: Kanda, Junya
  organization: Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University
– sequence: 5
  givenname: Toshimitsu
  surname: Ueki
  fullname: Ueki, Toshimitsu
  organization: Department of Hematology, Nagano Red Cross Hospital
– sequence: 6
  givenname: Fumihiko
  orcidid: 0000-0001-6223-9904
  surname: Kimura
  fullname: Kimura, Fumihiko
  organization: Division of Hematology, National Defense Medical College
– sequence: 7
  givenname: Koji
  surname: Kato
  fullname: Kato, Koji
  organization: Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences
– sequence: 8
  givenname: Naoyuki
  surname: Uchida
  fullname: Uchida, Naoyuki
  organization: Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital
– sequence: 9
  givenname: Kazuhiro
  surname: Ikegame
  fullname: Ikegame, Kazuhiro
  organization: Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine
– sequence: 10
  givenname: Makoto
  surname: Onizuka
  fullname: Onizuka, Makoto
  organization: Department of Hematology and Oncology, Tokai University School of Medicine
– sequence: 11
  givenname: Ken-ichi
  surname: Matsuoka
  fullname: Matsuoka, Ken-ichi
  organization: Department of Hematology and Oncology, Okayama University Hospital
– sequence: 12
  givenname: Noriko
  surname: Doki
  fullname: Doki, Noriko
  organization: Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital
– sequence: 13
  givenname: Toshiro
  surname: Kawakita
  fullname: Kawakita, Toshiro
  organization: Department of Hematology, National Hospital Organization Kumamoto Medical Center
– sequence: 14
  givenname: Yasushi
  surname: Onishi
  fullname: Onishi, Yasushi
  organization: Department of Hematology and Rheumatology, Tohoku University Hospital
– sequence: 15
  givenname: Shingo
  surname: Yano
  fullname: Yano, Shingo
  organization: Clinical oncology and Hematology, The Jikei University School of Medicine
– sequence: 16
  givenname: Takahiro
  surname: Fukuda
  fullname: Fukuda, Takahiro
  organization: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital
– sequence: 17
  givenname: Minoko
  surname: Takanashi
  fullname: Takanashi, Minoko
  organization: Blood Service Headquarters, Japanese Red Cross Society
– sequence: 18
  givenname: Yoshinobu
  surname: Kanda
  fullname: Kanda, Yoshinobu
  organization: Division of Hematology, Jichi Medical University Saitama Medical Center
– sequence: 19
  givenname: Yoshiko
  surname: Atsuta
  fullname: Atsuta, Yoshiko
  organization: Japanese Data Center for Hematopoietic Cell Transplantation, Department of Healthcare Administration, Nagoya University Graduate School of Medicine
– sequence: 20
  givenname: Masao
  orcidid: 0000-0002-4896-5878
  surname: Ogata
  fullname: Ogata, Masao
  organization: Department of Hematology, Oita University Hospital
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32051535$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1rFDEUhgep2G31B3gjAUG8mZqvyUwuy-IXFLzR65DNnMymZJI1yVj8Q_5Os25L7aIlFwmH531zkvOeNSchBmialwRfEMyGd5kTjmWLKW7xQEkrnzQrwnvRdkx0J80KUzG0jAl52pzlfI0x4Rx3z5pTRnFHOtatml_rOO90cjkGFC0qW0BxKSbOkJG2BRLa6p2PboRQnNEe6TAiE9OINj7GEWXtf-gJUEk65J3XoejiYsjIxoSmVC2Q1c4vCWrF-3jjwoR0PUwQwBm0hVmXuIsOqj3KBWZkwPtjv-fNU6t9hhe3-3nz7cP7r-tP7dWXj5_Xl1et6QQvLQFsudmMlFgxGKCCS-Cst3qDx5HoWuM9l1YaiYWhQg580COhduzE0Ntuw86btwffXYrfF8hFzS7vG9IB4pIVZR3vmaAcV_T1EXodlxRqd4ryvsNEDlg8TrFeMMk4u6cm7UG5YGN9v9lfrS4FY_1AJaGVuvgHVdcIszM1GtbV-gPBm78EW9C-bHP0y58JPQRf3Xa5bGYY1S65Waef6i4nFegPgEkx5wRWGXeYTG3BeUWw2idSHRKpaiLVPpFKViU5Ut6ZP6ahB02ubJgg3X_a_0W_AenB8yY
CitedBy_id crossref_primary_10_1186_s13287_024_03726_z
crossref_primary_10_3346_jkms_2025_40_e48
crossref_primary_10_1038_s41409_021_01310_0
crossref_primary_10_1038_s41409_022_01840_1
crossref_primary_10_3389_fonc_2022_922120
crossref_primary_10_3390_cells13110993
crossref_primary_10_1007_s12185_022_03405_w
crossref_primary_10_3346_jkms_2021_36_e151
crossref_primary_10_1038_s41409_021_01323_9
crossref_primary_10_1111_ejh_13868
crossref_primary_10_1038_s41409_022_01761_z
crossref_primary_10_1016_j_beha_2021_101284
crossref_primary_10_1038_s41409_024_02276_5
crossref_primary_10_3389_fimmu_2022_980464
crossref_primary_10_1016_j_jtct_2021_10_014
crossref_primary_10_1038_s41409_020_00999_9
crossref_primary_10_3389_fmed_2021_604085
crossref_primary_10_1016_j_bulcan_2022_09_003
crossref_primary_10_1038_s41409_023_02012_5
Cites_doi 10.1016/j.bbmt.2019.05.013
10.1002/ajh.25406
10.1016/j.bbmt.2010.09.005
10.1038/bmt.2015.351
10.1016/j.bbmt.2017.08.020
10.1016/j.transci.2018.04.014
10.1016/j.bbmt.2015.05.001
10.1016/j.bbmt.2009.07.004
10.1016/j.bbmt.2014.03.024
10.1007/s00277-015-2440-x
10.1155/2016/4025073
10.1038/leu.2015.75
10.1007/s12185-015-1907-9
10.1002/ajh.24111
10.1038/sj.bmt.1705312
10.1182/blood-2015-02-627786
10.1111/j.1365-2141.2005.05832.x
10.3324/haematol.2019.216101
10.1016/j.bbmt.2010.02.013
10.1016/j.bbmt.2012.02.014
10.4049/jimmunol.148.9.2953
10.1111/joim.12854
10.1182/blood.V88.3.962.962
10.1002/jcp.1041650312
10.1007/s12185-015-1894-x
10.1038/bmt.2011.84
10.1038/bmt.2014.250
10.1097/MOH.0000000000000382
10.1038/bmt.2017.58
10.1016/j.bbmt.2015.09.002
10.3389/fimmu.2016.00362
10.1002/ajh.23845
10.1038/bmt.2016.217
10.1182/blood-2012-03-418202
10.3324/haematol.2016.151779
10.1038/bmt.2015.229
10.1038/bmt.2012.239
10.1111/imj.13979
10.1038/bmt.2012.244
10.1038/bmt.2013.36
10.1038/bmt.2017.116
ContentType Journal Article
Contributor Ueki, Toshimitsu
Seo, Sachiko
Harada, Kaito
Fuji, Shigeo
Ogata, Masao
Contributor_xml – sequence: 1
  givenname: Kaito
  surname: Harada
  fullname: Harada, Kaito
– sequence: 2
  givenname: Shigeo
  surname: Fuji
  fullname: Fuji, Shigeo
– sequence: 3
  givenname: Sachiko
  surname: Seo
  fullname: Seo, Sachiko
– sequence: 4
  givenname: Toshimitsu
  surname: Ueki
  fullname: Ueki, Toshimitsu
– sequence: 5
  givenname: Masao
  surname: Ogata
  fullname: Ogata, Masao
Copyright The Author(s), under exclusive licence to Springer Nature Limited 2020
COPYRIGHT 2020 Nature Publishing Group
The Author(s), under exclusive licence to Springer Nature Limited 2020.
Copyright_xml – notice: The Author(s), under exclusive licence to Springer Nature Limited 2020
– notice: COPYRIGHT 2020 Nature Publishing Group
– notice: The Author(s), under exclusive licence to Springer Nature Limited 2020.
CorporateAuthor on behalf of the transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
CorporateAuthor_xml – name: on behalf of the transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
– name: transplant complications working group of the Japan Society for Hematopoietic Cell Transplantation
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QO
7QP
7T5
7U9
7X7
7XB
88E
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7N
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1038/s41409-020-0821-9
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Calcium & Calcified Tissue Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Algology Mycology and Protozoology Abstracts (Microbiology C)
Health & Medical Research Collection
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Virology and AIDS Abstracts
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
Immunology Abstracts
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList ProQuest Central Student
MEDLINE


MEDLINE - Academic

ProQuest Central Student
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Public Health
EISSN 1476-5365
EndPage 1795
ExternalDocumentID A633782912
32051535
10_1038_s41409_020_0821_9
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-Q-
.55
.XZ
0R~
23N
2WC
36B
39C
3V.
4.4
406
53G
5GY
5RE
6J9
70F
7X7
88E
8AO
8FI
8FJ
8R4
8R5
AACDK
AANZL
AASML
AATNV
AAYZH
AAZLF
ABAKF
ABAWZ
ABDBF
ABJNI
ABLJU
ABUWG
ABZZP
ACAOD
ACGFO
ACGFS
ACIWK
ACKTT
ACMJI
ACPRK
ACRQY
ACUHS
ACZOJ
ADBBV
ADFRT
ADHDB
AEFQL
AEJRE
AEMSY
AENEX
AEVLU
AEXYK
AFBBN
AFFNX
AFKRA
AFRAH
AFSHS
AGAYW
AGHAI
AGQEE
AHMBA
AHSBF
AIGIU
AILAN
AJRNO
ALFFA
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMYLF
ASPBG
AVWKF
AXYYD
AZFZN
B0M
BAWUL
BBNVY
BENPR
BHPHI
BKKNO
BPHCQ
BVXVI
CCPQU
CS3
DIK
DNIVK
DPUIP
DU5
E3Z
EAD
EAP
EBC
EBD
EBLON
EBS
EE.
EIOEI
EJD
EMB
EMK
EMOBN
EPL
ESX
EX3
F5P
FDQFY
FEDTE
FERAY
FIGPU
FIZPM
FRP
FSGXE
FYUFA
GX1
HCIFZ
HMCUK
HVGLF
HZ~
IAO
IH2
IHR
IHW
INH
INR
ITC
IWAJR
J5H
JSO
JZLTJ
KQ8
LGEZI
LOTEE
M1P
M7P
N9A
NADUK
NAO
NQJWS
NXXTH
O9-
OK1
OVD
P2P
PQQKQ
PROAC
PSQYO
Q2X
RNT
RNTTT
ROL
SNX
SNYQT
SOHCF
SOJ
SRMVM
SV3
SWTZT
TAOOD
TBHMF
TDRGL
TEORI
TR2
TSG
TUS
UDS
UKHRP
X7M
ZGI
ZXP
~8M
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
AEZWR
AFDZB
AFHIU
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ABRTQ
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
AEIIB
PMFND
7QO
7QP
7T5
7U9
7XB
8FD
8FE
8FH
8FK
AZQEC
DWQXO
FR3
GNUQQ
H94
K9.
LK8
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c564t-1e0f4cbd21f68ce2649e437fab0dd1a68c4749f9c906c269848ad12fd5687f5b3
IEDL.DBID 7X7
ISSN 0268-3369
1476-5365
IngestDate Fri Jul 11 07:54:35 EDT 2025
Fri Jul 25 09:05:55 EDT 2025
Sat Aug 23 12:50:26 EDT 2025
Tue Jun 17 21:26:19 EDT 2025
Tue Jun 10 20:40:40 EDT 2025
Thu May 22 21:20:27 EDT 2025
Mon Jul 21 05:46:51 EDT 2025
Tue Jul 01 03:21:52 EDT 2025
Thu Apr 24 22:58:04 EDT 2025
Fri Feb 21 02:40:22 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c564t-1e0f4cbd21f68ce2649e437fab0dd1a68c4749f9c906c269848ad12fd5687f5b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-6223-9904
0000-0002-8462-7550
0000-0002-6704-3633
0000-0002-4896-5878
PMID 32051535
PQID 2437639343
PQPubID 36075
PageCount 12
ParticipantIDs proquest_miscellaneous_2354736240
proquest_journals_2475019806
proquest_journals_2437639343
gale_infotracmisc_A633782912
gale_infotracacademiconefile_A633782912
gale_healthsolutions_A633782912
pubmed_primary_32051535
crossref_citationtrail_10_1038_s41409_020_0821_9
crossref_primary_10_1038_s41409_020_0821_9
springer_journals_10_1038_s41409_020_0821_9
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-09-01
PublicationDateYYYYMMDD 2020-09-01
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-01
  day: 01
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationSubtitle Official journal of the European Society for Blood and Marrow Transplantation
PublicationTitle Bone marrow transplantation (Basingstoke)
PublicationTitleAbbrev Bone Marrow Transplant
PublicationTitleAlternate Bone Marrow Transplant
PublicationYear 2020
Publisher Nature Publishing Group UK
Nature Publishing Group
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
References BacigalupoASormaniMPLamparelliTGualandiFOcchiniDBreganteSReducing transplant-related mortality after allogeneic hematopoietic stem cell transplantationHaematologica20048912384715477210
WakiFMasuokaKFukudaTKandaYNakamaeMYakushijinKFeasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patientsBiol Blood Marrow Transplant201117841512084996910.1016/j.bbmt.2010.09.005
NarimatsuHKamiMMiyakoshiSMurashigeNYujiKHamakiTGraft failure following reduced-intensity cord blood transplantation for adult patientsBr J Haematol200613236411637101810.1111/j.1365-2141.2005.05832.x
FujiSNakamuraFHatanakaKTaniguchiSSatoMMoriSPeripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell TransplantationBiol Blood Marrow Transplant2012181407142243008610.1016/j.bbmt.2012.02.014
KumarRBonfimCGeorgeBHematopoietic cell transplantation for aplastic anemiaCurr Opin Hematol201724509142887704210.1097/MOH.0000000000000382
RashidiASladeMDiPersioJFWesterveltPVijRRomeeRPost-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AMLBone Marrow Transplant201651156141:CAS:528:DC%2BC28XhtlOrsbvI2752628210.1038/bmt.2016.217
YoshiharaSIkegameKTaniguchiKKaidaKKimEHNakataJSalvage haploidentical transplantation for graft failure using reduced-intensity conditioningBone Marrow Transplant201247369731:CAS:528:DC%2BC38Xjs1Sms7k%3D2147892010.1038/bmt.2011.84
KandaYInvestigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplant20134845281:STN:280:DC%2BC3s7ovValug%3D%3D2320831310.1038/bmt.2012.244
OlssonRFLoganBRChaudhurySZhuXAkpekGBolwellBJPrimary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignanciesLeukemia2015291754621:CAS:528:DC%2BC2MXhtlWhsb7F25772027452788610.1038/leu.2015.75
OlssonRRembergerMSchafferMBerggrenDMSvahnBMMattssonJGraft failure in the modern era of allogeneic hematopoietic SCTBone Marrow Transplant201348537431:CAS:528:DC%2BC3sXlsVeqsL0%3D2322238410.1038/bmt.2012.239
SelleriCSatoTAndersonSYoungNSMaciejewskiJPInterferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell deathJ Cell Physiol1995165538461:CAS:528:DyaK2MXpslalsbk%3D759323310.1002/jcp.1041650312
LundTCLiegelJBejanyanNOrchardPJCaoQTolarJSecond allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failureAm J Hematol201590892626149534457900610.1002/ajh.24111
BacigalupoABallenKRizzoDGiraltSLazarusHHoVDefining the intensity of conditioning regimens: working definitionsBiol Blood Marrow Transplant20091516283319896087286165610.1016/j.bbmt.2009.07.004
AlcazerVConradAValourFBachyESallesGHuynhAEarly-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failureAm J Hematol201994E109113066308910.1002/ajh.25406
MartinPJPrevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanismBlood19968896291:CAS:528:DyaK28Xks1Cjtbw%3D870425510.1182/blood.V88.3.962.962
CiureaSOThallPFMiltonDRBarnesTHKongtimPCarmazziYComplement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantationBiol Blood Marrow Transplant201521139281:CAS:528:DC%2BC2MXhtVeksLzM25985919450671610.1016/j.bbmt.2015.05.001
ArmandPGibsonCJCutlerCHoVTKorethJAlyeaEPA disease risk index for patients undergoing allogeneic stem cell transplantationBlood2012120905131:CAS:528:DC%2BC38XhtFOgurvO22709687341235110.1182/blood-2012-03-418202
OzdemirZNCivriz BozdağSGraft failure after allogeneic hematopoietic stem cell transplantationTransfus Apher Sci20185716372972462710.1016/j.transci.2018.04.014
nccn.org [internet]. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3. 2019. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 11 Aug.
DaviesSMWeisdorfDJHaakeRJKerseyJHMcGlavePBRamsayNKSecond infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantationBone Marrow Transplant1994147371:STN:280:DyaK2M%2FjvVKitg%3D%3D7951123
SullivanKMAguraEAnasettiCAppelbaumFBadgerCBearmanSChronic graft-versus-host disease and other late complications of bone marrow transplantationSemin Hematol19912825091:STN:280:DyaK3MzmtFWjug%3D%3D1887253
CluzeauTLambertJRausNDessauxKAbsiLDelbosFRisk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHIBone Marrow Transplant201651687911:CAS:528:DC%2BC28Xis1aks7k%3D2685515810.1038/bmt.2015.351
SunYQHeGLChangYJXuLPZhangXHHanWThe incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantationAnn Hematol20159416997051:CAS:528:DC%2BC2MXhtFyqsLrN2615255310.1007/s00277-015-2440-x
KatoMMatsumotoKSuzukiRYabeHInoueMKigasawaHSalvage allogeneic hematopoietic SCT for primary graft failure in childrenBone Marrow Transplant201348117381:STN:280:DC%2BC3svptVaisw%3D%3D2352463910.1038/bmt.2013.36
Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Del Bufalo F, et al. Role of IFNγ in immune-mediated graft failure occurring after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019. https://doi.org/10.3324/haematol.2019.216101.
BasheyAZhangXJacksonKBrownSRidgewayMSolhMComparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and hla-identical sibling donors: a multivariable analysis including disease risk indexBiol Blood Marrow Transplant201622125331:CAS:528:DC%2BC2MXhsFKqt7vL2635988110.1016/j.bbmt.2015.09.002
CanaaniJBeohouELabopinMGhavamzadehABeelenDHamladjiRMTrends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysisJ Intern Med2019285407181:CAS:528:DC%2BC1MXls1Klu7Y%3D3037279610.1111/joim.12854
OnishiYMoriTKakoSKohHUchidaNKondoTOutcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemiaBiol Blood Marrow Transplant2017232137422884494710.1016/j.bbmt.2017.08.020
SinghHNikiforowSLiSBallenKKSpitzerTRSoifferROutcomes and management strategies for graft failure after umbilical cord blood transplantationAm J Hematol20148910971012519550010.1002/ajh.23845
KandaJScripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantationInt J Hematol20161031191:CAS:528:DC%2BC2MXhvFCqtLzK2658892710.1007/s12185-015-1907-9
TerakuraSKuwatsukaYYamasakiSWakeAKandaJInamotoYGvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemiaBone Marrow Transplant201752126171:STN:280:DC%2BC1cnntlalsQ%3D%3D2860466510.1038/bmt.2017.116
SchriberJAgoviMAHoVBallenKKBacigalupoALazarusHMSecond unrelated donor hematopoietic cell transplantation for primary graft failureBiol Blood Marrow Transplant201016109910620172038289795310.1016/j.bbmt.2010.02.013
PrzepiorkaDWeisdorfDMartinPKlingemannHGBeattyPHowsJ1994 Consensus Conference on Acute GVHD GradingBone Marrow Transplant19951582581:STN:280:DyaK28%2Fot1Ojtw%3D%3D7581076
KawashimaNTerakuraSNishiwakiSKoyamaDOzawaYItoMIncrease of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantationBone Marrow Transplant2017521164701:CAS:528:DC%2BC2sXlslGjuro%3D2836837410.1038/bmt.2017.58
RuggeriASunYLabopinMBacigalupoALorentinoFArceseWPost-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantHaematologica20171024011027758821528694810.3324/haematol.2016.151779
KlimanDBilmonIKwanJBlythEMicklethwaiteKPanickerSRescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case seriesIntern Med J201848988911:CAS:528:DC%2BC1cXhsVOjurrE3013398710.1111/imj.13979
KongYWangYTHuYHanWChangYJZhangXHThe bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft functionBone Marrow Transplant201651249551:CAS:528:DC%2BC2MXhs1Cht7rM2643706610.1038/bmt.2015.229
WangYLiuQFXuLPLiuKYZhangXHMaXHaploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective studyBlood20151253956621:CAS:528:DC%2BC2MXhtFCmsbzE2594071410.1182/blood-2015-02-627786
Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019. https://doi.org/10.1016/j.bbmt.2019.05.013.
AtsutaYIntroduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)Int J Hematol20161033102654757010.1007/s12185-015-1894-x
KongtimPCaoKCiureaSODonor specific Anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantationAdv Hematol20162016402507326904122474527510.1155/2016/40250731:CAS:528:DC%2BC1cXnvFOhsrY%3D
ShimadaKNarimatsuHMorishitaYKohnoASaitoSKatoYSevere regimen-related toxicity of second transplantation for graft failure following reduced-intensity cord blood transplantation in an adult patientBone Ma
YQ Sun (821_CR9) 2015; 94
Y Kong (821_CR17) 2016; 51
M Kato (821_CR44) 2013; 48
A Rashidi (821_CR28) 2016; 51
S Masouridi-Levrat (821_CR10) 2016; 7
SM Davies (821_CR27) 1994; 14
TC Lund (821_CR25) 2015; 90
A Bacigalupo (821_CR39) 2009; 15
ZN Ozdemir (821_CR11) 2018; 57
KM Sullivan (821_CR42) 1991; 28
P Kongtim (821_CR16) 2016; 2016
Y Wang (821_CR30) 2015; 125
PJ Martin (821_CR13) 1996; 88
Y Atsuta (821_CR37) 2016; 103
H Singh (821_CR31) 2014; 89
F Moscardó (821_CR34) 2014; 20
J Kanda (821_CR38) 2016; 103
A Ruggeri (821_CR45) 2017; 102
R Kumar (821_CR2) 2017; 24
N Kawashima (821_CR12) 2017; 52
J Canaani (821_CR3) 2019; 285
Y Onishi (821_CR24) 2017; 23
K Shimada (821_CR26) 2006; 37
821_CR1
T Cluzeau (821_CR8) 2016; 51
J Schriber (821_CR21) 2010; 16
V Alcazer (821_CR20) 2019; 94
F Waki (821_CR23) 2011; 17
P Armand (821_CR40) 2012; 120
WJ Murphy (821_CR14) 1992; 148
SO Ciurea (821_CR15) 2015; 21
A Bacigalupo (821_CR4) 2004; 89
Y Kanda (821_CR43) 2013; 48
A Bashey (821_CR29) 2016; 22
D Kliman (821_CR32) 2018; 48
821_CR36
R Olsson (821_CR6) 2013; 48
C Selleri (821_CR18) 1995; 165
S Yoshihara (821_CR33) 2012; 47
S Terakura (821_CR46) 2017; 52
821_CR19
H Narimatsu (821_CR5) 2006; 132
S Fuji (821_CR22) 2012; 18
BL Tang (821_CR35) 2015; 50
D Przepiorka (821_CR41) 1995; 15
RF Olsson (821_CR7) 2015; 29
References_xml – reference: KandaJScripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantationInt J Hematol20161031191:CAS:528:DC%2BC2MXhvFCqtLzK2658892710.1007/s12185-015-1907-9
– reference: KongtimPCaoKCiureaSODonor specific Anti-HLA antibody and risk of graft failure in haploidentical stem cell transplantationAdv Hematol20162016402507326904122474527510.1155/2016/40250731:CAS:528:DC%2BC1cXnvFOhsrY%3D
– reference: CiureaSOThallPFMiltonDRBarnesTHKongtimPCarmazziYComplement-binding donor-specific anti-HLA antibodies and risk of primary graft failure in hematopoietic stem cell transplantationBiol Blood Marrow Transplant201521139281:CAS:528:DC%2BC2MXhtVeksLzM25985919450671610.1016/j.bbmt.2015.05.001
– reference: nccn.org [internet]. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. Acute Myeloid Leukemia. Version 3. 2019. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 11 Aug.
– reference: OlssonRRembergerMSchafferMBerggrenDMSvahnBMMattssonJGraft failure in the modern era of allogeneic hematopoietic SCTBone Marrow Transplant201348537431:CAS:528:DC%2BC3sXlsVeqsL0%3D2322238410.1038/bmt.2012.239
– reference: MurphyWJBennettMKumarVLongoDLDonor-type activated natural killer cells promote marrow engraftment and B cell development during allogeneic bone marrow transplantationJ Immunol19921482953601:CAS:528:DyaK38XisFeqsLo%3D1573278
– reference: DaviesSMWeisdorfDJHaakeRJKerseyJHMcGlavePBRamsayNKSecond infusion of bone marrow for treatment of graft failure after allogeneic bone marrow transplantationBone Marrow Transplant1994147371:STN:280:DyaK2M%2FjvVKitg%3D%3D7951123
– reference: BasheyAZhangXJacksonKBrownSRidgewayMSolhMComparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and hla-identical sibling donors: a multivariable analysis including disease risk indexBiol Blood Marrow Transplant201622125331:CAS:528:DC%2BC2MXhsFKqt7vL2635988110.1016/j.bbmt.2015.09.002
– reference: OzdemirZNCivriz BozdağSGraft failure after allogeneic hematopoietic stem cell transplantationTransfus Apher Sci20185716372972462710.1016/j.transci.2018.04.014
– reference: SelleriCSatoTAndersonSYoungNSMaciejewskiJPInterferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell deathJ Cell Physiol1995165538461:CAS:528:DyaK2MXpslalsbk%3D759323310.1002/jcp.1041650312
– reference: RuggeriASunYLabopinMBacigalupoALorentinoFArceseWPost-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus-host disease prophylaxis in haploidentical transplantHaematologica20171024011027758821528694810.3324/haematol.2016.151779
– reference: Masouridi-LevratSSimonettaFChalandonYImmunological basis of bone marrow failure after allogeneic hematopoietic stem cell transplantationFront Immunol2016736227695456502542910.3389/fimmu.2016.003621:CAS:528:DC%2BC1cXpsVSisQ%3D%3D
– reference: Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Del Bufalo F, et al. Role of IFNγ in immune-mediated graft failure occurring after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019. https://doi.org/10.3324/haematol.2019.216101.
– reference: PrzepiorkaDWeisdorfDMartinPKlingemannHGBeattyPHowsJ1994 Consensus Conference on Acute GVHD GradingBone Marrow Transplant19951582581:STN:280:DyaK28%2Fot1Ojtw%3D%3D7581076
– reference: SullivanKMAguraEAnasettiCAppelbaumFBadgerCBearmanSChronic graft-versus-host disease and other late complications of bone marrow transplantationSemin Hematol19912825091:STN:280:DyaK3MzmtFWjug%3D%3D1887253
– reference: KandaYInvestigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplant20134845281:STN:280:DC%2BC3s7ovValug%3D%3D2320831310.1038/bmt.2012.244
– reference: NarimatsuHKamiMMiyakoshiSMurashigeNYujiKHamakiTGraft failure following reduced-intensity cord blood transplantation for adult patientsBr J Haematol200613236411637101810.1111/j.1365-2141.2005.05832.x
– reference: SunYQHeGLChangYJXuLPZhangXHHanWThe incidence, risk factors, and outcomes of primary poor graft function after unmanipulated haploidentical stem cell transplantationAnn Hematol20159416997051:CAS:528:DC%2BC2MXhtFyqsLrN2615255310.1007/s00277-015-2440-x
– reference: CanaaniJBeohouELabopinMGhavamzadehABeelenDHamladjiRMTrends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukaemia: an ALWP/EBMT analysisJ Intern Med2019285407181:CAS:528:DC%2BC1MXls1Klu7Y%3D3037279610.1111/joim.12854
– reference: YoshiharaSIkegameKTaniguchiKKaidaKKimEHNakataJSalvage haploidentical transplantation for graft failure using reduced-intensity conditioningBone Marrow Transplant201247369731:CAS:528:DC%2BC38Xjs1Sms7k%3D2147892010.1038/bmt.2011.84
– reference: RashidiASladeMDiPersioJFWesterveltPVijRRomeeRPost-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AMLBone Marrow Transplant201651156141:CAS:528:DC%2BC28XhtlOrsbvI2752628210.1038/bmt.2016.217
– reference: MartinPJPrevention of allogeneic marrow graft rejection by donor T cells that do not recognize recipient alloantigens: potential role of a veto mechanismBlood19968896291:CAS:528:DyaK28Xks1Cjtbw%3D870425510.1182/blood.V88.3.962.962
– reference: SchriberJAgoviMAHoVBallenKKBacigalupoALazarusHMSecond unrelated donor hematopoietic cell transplantation for primary graft failureBiol Blood Marrow Transplant201016109910620172038289795310.1016/j.bbmt.2010.02.013
– reference: KongYWangYTHuYHanWChangYJZhangXHThe bone marrow microenvironment is similarly impaired in allogeneic hematopoietic stem cell transplantation patients with early and late poor graft functionBone Marrow Transplant201651249551:CAS:528:DC%2BC2MXhs1Cht7rM2643706610.1038/bmt.2015.229
– reference: OnishiYMoriTKakoSKohHUchidaNKondoTOutcome of second transplantation using umbilical cord blood for graft failure after allogeneic hematopoietic stem cell transplantation for aplastic anemiaBiol Blood Marrow Transplant2017232137422884494710.1016/j.bbmt.2017.08.020
– reference: BacigalupoASormaniMPLamparelliTGualandiFOcchiniDBreganteSReducing transplant-related mortality after allogeneic hematopoietic stem cell transplantationHaematologica20048912384715477210
– reference: AlcazerVConradAValourFBachyESallesGHuynhAEarly-onset severe infections in allogeneic hematopoietic stem cell transplantation recipients with graft failureAm J Hematol201994E109113066308910.1002/ajh.25406
– reference: TerakuraSKuwatsukaYYamasakiSWakeAKandaJInamotoYGvHD prophylaxis after single-unit reduced intensity conditioning cord blood transplantation in adults with acute leukemiaBone Marrow Transplant201752126171:STN:280:DC%2BC1cnntlalsQ%3D%3D2860466510.1038/bmt.2017.116
– reference: Prata PH, Resche-Rigon M, Blaise D, Socié G, Rohrlich PS, Milpied N, et al. Outcomes of salvage haploidentical transplant with post-transplant cyclophosphamide for rescuing graft failure patients: a report on behalf of the francophone society of bone marrow transplantation and cellular therapy. Biol Blood Marrow Transplant. 2019. https://doi.org/10.1016/j.bbmt.2019.05.013.
– reference: OlssonRFLoganBRChaudhurySZhuXAkpekGBolwellBJPrimary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignanciesLeukemia2015291754621:CAS:528:DC%2BC2MXhtlWhsb7F25772027452788610.1038/leu.2015.75
– reference: CluzeauTLambertJRausNDessauxKAbsiLDelbosFRisk factors and outcome of graft failure after HLA matched and mismatched unrelated donor hematopoietic stem cell transplantation: a study on behalf of SFGM-TC and SFHIBone Marrow Transplant201651687911:CAS:528:DC%2BC28Xis1aks7k%3D2685515810.1038/bmt.2015.351
– reference: WangYLiuQFXuLPLiuKYZhangXHMaXHaploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective studyBlood20151253956621:CAS:528:DC%2BC2MXhtFCmsbzE2594071410.1182/blood-2015-02-627786
– reference: MoscardóFRomeroSSanzJSanzMAMontesinosPLorenzoIT cell-depleted related HLA-mismatched peripheral blood stem cell transplantation as salvage therapy for graft failure after single unit unrelated donor umbilical cord blood transplantationBiol Blood Marrow Transplant201420106032468557810.1016/j.bbmt.2014.03.0241:CAS:528:DC%2BC2cXotFOrt7s%3D
– reference: FujiSNakamuraFHatanakaKTaniguchiSSatoMMoriSPeripheral blood as a preferable source of stem cells for salvage transplantation in patients with graft failure after cord blood transplantation: a retrospective analysis of the registry data of the Japanese Society for Hematopoietic Cell TransplantationBiol Blood Marrow Transplant2012181407142243008610.1016/j.bbmt.2012.02.014
– reference: SinghHNikiforowSLiSBallenKKSpitzerTRSoifferROutcomes and management strategies for graft failure after umbilical cord blood transplantationAm J Hematol20148910971012519550010.1002/ajh.23845
– reference: BacigalupoABallenKRizzoDGiraltSLazarusHHoVDefining the intensity of conditioning regimens: working definitionsBiol Blood Marrow Transplant20091516283319896087286165610.1016/j.bbmt.2009.07.004
– reference: KawashimaNTerakuraSNishiwakiSKoyamaDOzawaYItoMIncrease of bone marrow macrophages and CD8+ T lymphocytes predict graft failure after allogeneic bone marrow or cord blood transplantationBone Marrow Transplant2017521164701:CAS:528:DC%2BC2sXlslGjuro%3D2836837410.1038/bmt.2017.58
– reference: LundTCLiegelJBejanyanNOrchardPJCaoQTolarJSecond allogeneic hematopoietic cell transplantation for graft failure: poor outcomes for neutropenic graft failureAm J Hematol201590892626149534457900610.1002/ajh.24111
– reference: KlimanDBilmonIKwanJBlythEMicklethwaiteKPanickerSRescue haploidentical peripheral blood stem cell transplantation for engraftment failure: a single-centre case seriesIntern Med J201848988911:CAS:528:DC%2BC1cXhsVOjurrE3013398710.1111/imj.13979
– reference: KatoMMatsumotoKSuzukiRYabeHInoueMKigasawaHSalvage allogeneic hematopoietic SCT for primary graft failure in childrenBone Marrow Transplant201348117381:STN:280:DC%2BC3svptVaisw%3D%3D2352463910.1038/bmt.2013.36
– reference: AtsutaYIntroduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)Int J Hematol20161033102654757010.1007/s12185-015-1894-x
– reference: ShimadaKNarimatsuHMorishitaYKohnoASaitoSKatoYSevere regimen-related toxicity of second transplantation for graft failure following reduced-intensity cord blood transplantation in an adult patientBone Marrow Transplant20063778781:STN:280:DC%2BD287ovFOhug%3D%3D1650158910.1038/sj.bmt.1705312
– reference: WakiFMasuokaKFukudaTKandaYNakamaeMYakushijinKFeasibility of reduced-intensity cord blood transplantation as salvage therapy for graft failure: results of a nationwide survey of adult patientsBiol Blood Marrow Transplant201117841512084996910.1016/j.bbmt.2010.09.005
– reference: ArmandPGibsonCJCutlerCHoVTKorethJAlyeaEPA disease risk index for patients undergoing allogeneic stem cell transplantationBlood2012120905131:CAS:528:DC%2BC38XhtFOgurvO22709687341235110.1182/blood-2012-03-418202
– reference: KumarRBonfimCGeorgeBHematopoietic cell transplantation for aplastic anemiaCurr Opin Hematol201724509142887704210.1097/MOH.0000000000000382
– reference: TangBLZhuXYZhengCCLiuHLGengLQWangXBSuccessful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patientsBone Marrow Transplant201550248521:CAS:528:DC%2BC2cXhvVOntr%2FP2536506710.1038/bmt.2014.250
– volume: 89
  start-page: 1238
  year: 2004
  ident: 821_CR4
  publication-title: Haematologica
– ident: 821_CR36
  doi: 10.1016/j.bbmt.2019.05.013
– volume: 94
  start-page: E109
  year: 2019
  ident: 821_CR20
  publication-title: Am J Hematol
  doi: 10.1002/ajh.25406
– volume: 17
  start-page: 841
  year: 2011
  ident: 821_CR23
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.09.005
– volume: 51
  start-page: 687
  year: 2016
  ident: 821_CR8
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2015.351
– volume: 15
  start-page: 825
  year: 1995
  ident: 821_CR41
  publication-title: Bone Marrow Transplant
– volume: 23
  start-page: 2137
  year: 2017
  ident: 821_CR24
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2017.08.020
– volume: 57
  start-page: 163
  year: 2018
  ident: 821_CR11
  publication-title: Transfus Apher Sci
  doi: 10.1016/j.transci.2018.04.014
– volume: 21
  start-page: 1392
  year: 2015
  ident: 821_CR15
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2015.05.001
– volume: 15
  start-page: 1628
  year: 2009
  ident: 821_CR39
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2009.07.004
– volume: 20
  start-page: 1060
  year: 2014
  ident: 821_CR34
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2014.03.024
– volume: 94
  start-page: 1699
  year: 2015
  ident: 821_CR9
  publication-title: Ann Hematol
  doi: 10.1007/s00277-015-2440-x
– volume: 2016
  start-page: 4025073
  year: 2016
  ident: 821_CR16
  publication-title: Adv Hematol
  doi: 10.1155/2016/4025073
– volume: 29
  start-page: 1754
  year: 2015
  ident: 821_CR7
  publication-title: Leukemia
  doi: 10.1038/leu.2015.75
– volume: 103
  start-page: 11
  year: 2016
  ident: 821_CR38
  publication-title: Int J Hematol
  doi: 10.1007/s12185-015-1907-9
– ident: 821_CR1
– volume: 90
  start-page: 892
  year: 2015
  ident: 821_CR25
  publication-title: Am J Hematol
  doi: 10.1002/ajh.24111
– volume: 37
  start-page: 787
  year: 2006
  ident: 821_CR26
  publication-title: Bone Marrow Transplant
  doi: 10.1038/sj.bmt.1705312
– volume: 125
  start-page: 3956
  year: 2015
  ident: 821_CR30
  publication-title: Blood
  doi: 10.1182/blood-2015-02-627786
– volume: 28
  start-page: 250
  year: 1991
  ident: 821_CR42
  publication-title: Semin Hematol
– volume: 132
  start-page: 36
  year: 2006
  ident: 821_CR5
  publication-title: Br J Haematol
  doi: 10.1111/j.1365-2141.2005.05832.x
– ident: 821_CR19
  doi: 10.3324/haematol.2019.216101
– volume: 16
  start-page: 1099
  year: 2010
  ident: 821_CR21
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2010.02.013
– volume: 18
  start-page: 1407
  year: 2012
  ident: 821_CR22
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2012.02.014
– volume: 148
  start-page: 2953
  year: 1992
  ident: 821_CR14
  publication-title: J Immunol
  doi: 10.4049/jimmunol.148.9.2953
– volume: 285
  start-page: 407
  year: 2019
  ident: 821_CR3
  publication-title: J Intern Med
  doi: 10.1111/joim.12854
– volume: 88
  start-page: 962
  year: 1996
  ident: 821_CR13
  publication-title: Blood
  doi: 10.1182/blood.V88.3.962.962
– volume: 165
  start-page: 538
  year: 1995
  ident: 821_CR18
  publication-title: J Cell Physiol
  doi: 10.1002/jcp.1041650312
– volume: 103
  start-page: 3
  year: 2016
  ident: 821_CR37
  publication-title: Int J Hematol
  doi: 10.1007/s12185-015-1894-x
– volume: 47
  start-page: 369
  year: 2012
  ident: 821_CR33
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2011.84
– volume: 50
  start-page: 248
  year: 2015
  ident: 821_CR35
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2014.250
– volume: 24
  start-page: 509
  year: 2017
  ident: 821_CR2
  publication-title: Curr Opin Hematol
  doi: 10.1097/MOH.0000000000000382
– volume: 52
  start-page: 1164
  year: 2017
  ident: 821_CR12
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2017.58
– volume: 22
  start-page: 125
  year: 2016
  ident: 821_CR29
  publication-title: Biol Blood Marrow Transplant
  doi: 10.1016/j.bbmt.2015.09.002
– volume: 7
  start-page: 362
  year: 2016
  ident: 821_CR10
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2016.00362
– volume: 89
  start-page: 1097
  year: 2014
  ident: 821_CR31
  publication-title: Am J Hematol
  doi: 10.1002/ajh.23845
– volume: 51
  start-page: 1561
  year: 2016
  ident: 821_CR28
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2016.217
– volume: 14
  start-page: 73
  year: 1994
  ident: 821_CR27
  publication-title: Bone Marrow Transplant
– volume: 120
  start-page: 905
  year: 2012
  ident: 821_CR40
  publication-title: Blood
  doi: 10.1182/blood-2012-03-418202
– volume: 102
  start-page: 401
  year: 2017
  ident: 821_CR45
  publication-title: Haematologica
  doi: 10.3324/haematol.2016.151779
– volume: 51
  start-page: 249
  year: 2016
  ident: 821_CR17
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2015.229
– volume: 48
  start-page: 537
  year: 2013
  ident: 821_CR6
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2012.239
– volume: 48
  start-page: 988
  year: 2018
  ident: 821_CR32
  publication-title: Intern Med J
  doi: 10.1111/imj.13979
– volume: 48
  start-page: 452
  year: 2013
  ident: 821_CR43
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2012.244
– volume: 48
  start-page: 1173
  year: 2013
  ident: 821_CR44
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2013.36
– volume: 52
  start-page: 1261
  year: 2017
  ident: 821_CR46
  publication-title: Bone Marrow Transplant
  doi: 10.1038/bmt.2017.116
SSID ssj0014405
Score 2.4246686
Snippet Graft failure (GF) is a life-threatening complication after allogeneic stem cell transplantation (SCT). Although salvage SCTs can be performed with...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1784
SubjectTerms 692/699
692/700/1750
Antithymocyte globulin
Blood
Cell Biology
Comparative analysis
Cord blood
Engraftment
Fatalities
Fetal Blood
Graft rejection
Graft vs Host Disease
Graft-versus-host reaction
Grafting
Grafts
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic stem cells
Humans
Internal Medicine
Medicine
Medicine & Public Health
Mortality
Public Health
Stem cell transplantation
Stem Cells
Transplantation
Transplantation Conditioning
Transplants & implants
Title Comparison of the outcomes after haploidentical and cord blood salvage transplantations for graft failure following allogeneic hematopoietic stem cell transplantation
URI https://link.springer.com/article/10.1038/s41409-020-0821-9
https://www.ncbi.nlm.nih.gov/pubmed/32051535
https://www.proquest.com/docview/2437639343
https://www.proquest.com/docview/2475019806
https://www.proquest.com/docview/2354736240
Volume 55
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9UwFA-6gfgizs_qnBEEQSlrmzQ3eZJtbkzFIeLgvoU0TfRCaa9rr_5H-zt3Tvox74Xtsc1pmvbkfCTn5HcIeSsym1oGnpuwBY95CQtWZQsWmyy3DkySK0xA-zwTp-f8yzyfDxtu7ZBWOerEoKjLxuIe-T4C54E1ZZx9XP6JsWoURleHEhp3yTZCl2FK12w-Lbgwbpn3eywyZkyoMarJ5H7LEekpxsUTGEEY4Jpd2tTO_5mnjXhpMEMnD8mDwX-kBz3Dd8gdVz8i974NEfLH5PJoKixIG0_BvaPNqoNPdC0N9cDpb7OsmkU4nwv8oaYuKa5AaUhhp62p_oKKoV0APa9MfzKpbik4t_TXBXRBvVlgLjvcqarmH4ySYvAeJqJbWBowYJtls8DDkRRRoinGBjb7e0LOT45_Hp3GQy2G2OaCd3HqEs9tUWapF9I6cKOUA454UyRlmRq4x2dceWVVImwmlOTSlGnmy1zImc8L9pRs1U3tnhPKjXcyNYhMJjnnqsizmRHMJ14U0lgVkWTkhLYDUDnWy6h0CJgzqXvmaWCeRuZpeOT99MiyR-m4jfg1slf3B00nCdcHgjHwl1SaReRdoEAZhzdbMxxVgPEjWtYa5e4aJcimXW8ep5AedEOrr2fyDc3gxKVKJiIib6Zm7BjT4WrXrICGYcloAd5YRJ71M3P6bpZh2R6WR-TDOFWvO7_xp7y4faQvyf0syAom1-2Sre5i5V6BN9YVe0Hk9sj24fHZ9x9w9enz1yvggTQa
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BqdBLwgvikMZiQQEihaYjuu_YDQGJs6tlUIbdLeguPYUClKytIy8Yd45Ddyl6_RStvbXuPL1fWd7yP3RcgryWxkOVhu0qYiEBk4rNqmPDAstg5UkktN3e1zIscn4vNpfLpG_na1MJhW2cnEWlBnpcVv5FvYOA-0KRf8w-xngFOjMLrajdBo2OLA_T4Hl616v_8J6Puasb3d451x0E4VCGwsxTyIXOiFTTMWeamsA4NAO8DtTRpmWWTgmRgJ7bXVobRMaiWUySLms1iqkY9TDnhvkHXBwZUZkPWPu5MvX_u4hRBN0iSTKuBc6i6OytVWJbC3VIDuGqhdOJIlTbiqD_5TiCsR2lrx7d0ld1qLlW43LHaPrLniPrl51MbkH5A_O_0oQ1p6CgYlLRdzOFRX0XoCOf1hZnk5rSuCgSOoKTKKPi-tk-ZpZfJfINTovG6znpumFqqoKJjT9PsZoKDeTDF7Hp7keXkOu6SYLgCs76aW1l1ny1k5xXJMin2pKUYjVvE9JCfXQqdHZFCUhXtCqDDeqchgLzQlhNBpzEZGch96mSpj9ZCEHSUS27ZGxwkdeVKH6LlKGuIlQLwEiZfAK2_7V2ZNX5CrgDeRvElT2trLlGRbcg4Wmo7YkLypIVCqwC9b0xZHwP6xP9cS5MYSJEgDu7zcsVDSSqMqubg7lyyD2RhpFcohedkvI2JMwCtcuQAYjkOqJdh_Q_K44cz-f3OGg4J4PCTvOla9QH7poTy9eqeb5Nb4-OgwOdyfHDwjt1l9bzC1b4MM5mcL9xxswXn6or2AlHy77jv_D-I3cCQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3JbtQw1CpFqrggdgYKNRIICRRNYjse-4BQ1TJqKVQcqNRbcBwbRoqSoZmh4of4CL6O95ylzEjtrdfYcRy_3W8j5KVkNrEcNDdpcxGJAgxWbXMeGZZaByLJ5SZU-zyWByfi42l6ukH-9rkwGFbZ88TAqIva4h35GAvngTTlgo99FxbxZX_6fv4zwg5S6Gnt22m0KHLkfp-D-da8O9wHWL9ibPrh695B1HUYiGwqxSJKXOyFzQuWeKmsA-VAO_iON3lcFImBZ2IitNdWx9IyqZVQpkiYL1KpJj7NOax7g9yc8DRBGpucDsYe-kzT9n5HRZxL3XtUuRo3AqtMRWi4gQCGw1mRieuS4T_RuOarDSJweofc7nRXutsi212y4ap7ZOtz552_T_7sDU0Nae0pqJa0Xi7geF1DQy9y-sPMy3oWcoMBN6ipCorWLw3h87Qx5S9gb3QRCq6Xps2KqhoKijX9fgZLUG9mGEcPT8qyPoddUgwcACJwM0tD_dl6Xs8wMZNihWqKfon19R6Qk2uB0kOyWdWVe0yoMN6pxGBVNCWE0HnKJkZyH3uZK2P1iMQ9JDLbFUnHXh1lFpz1XGUt8DIAXobAy-CVN8Mr87ZCyFWTdxC8WZvkOnCXbFdyDrqaTtiIvA4zkL_Al63p0iRg_1ipa2Xm9spM4At2dbhHoazjS012QUWXDIMCmWgVyxF5MQzjwhiKV7l6CXM4tquWoAmOyKMWM4f_5gxbBvF0RN72qHqx-KWH8uTqne6QLaD07NPh8dFTcosFssEYv22yuThbumegFC7y54H6KPl23eT-D-_qcvQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+the+outcomes+after+haploidentical+and+cord+blood+salvage+transplantations+for+graft+failure+following+allogeneic+hematopoietic+stem+cell+transplantation&rft.jtitle=Bone+marrow+transplantation+%28Basingstoke%29&rft.au=Harada%2C+Kaito&rft.au=Fuji%2C+Shigeo&rft.au=Seo%2C+Sachiko&rft.au=Kanda%2C+Junya&rft.date=2020-09-01&rft.issn=0268-3369&rft.eissn=1476-5365&rft.volume=55&rft.issue=9&rft.spage=1784&rft.epage=1795&rft_id=info:doi/10.1038%2Fs41409-020-0821-9&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41409_020_0821_9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0268-3369&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0268-3369&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0268-3369&client=summon